Copenhagen, November 8, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule:
Deadline for submission of shareholder proposals to Annual General Meeting
February 12, 2019
Annual Report 2018
March 1, 2019
Annual General Meeting 2019
March 27, 2019
Interim Report First Half 2019
August 28, 2019